Loading clinical trials...
Loading clinical trials...
Comparison of the Effects of PEX20 (Oral Psilocin), PEX30 (Sublingual Psilocin), and PEX10 (Oral Psilocybin) in Healthy Adults
Conditions
Interventions
Psilocin
Psilocybin
+1 more
Locations
1
United States
University of California, San Francisco
San Francisco, California, United States
Start Date
May 26, 2022
Primary Completion Date
January 16, 2025
Completion Date
July 1, 2025
Last Updated
June 10, 2025
NCT00090662
NCT06716502
NCT07310264
NCT06290258
NCT07483606
NCT06342713
Lead Sponsor
University of California, San Francisco
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions